Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 569

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 4
Chunk 569
---
 are deemed to be a large accelerated filer under the rules of the SEC.

ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We
are not required to provide the information required by this Item as are a “smaller reporting company,” as defined in Rule
12b-2 of the Exchange Act.

-34-

ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

SYRA
HEALTH CORP.

INDEX
TO FINANCIAL STATEMENTS

    Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 2738)
     
    F-2

    Balance Sheets at December 31, 2024 and 2023
     
    F-3

    Statements of Operations for the Years Ended December 31, 2024 and 2023
     
    F-4

    Statements of Stockholders’ Equity for the Years Ended December 31, 2024 and 2023
     
    F-5

    Statements of Cash Flows for the Years Ended December 31, 2024 and 2023
     
    F-6

    Notes to the Financial Statements
     
    F-7

F-1

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To
the Board of Directors and

Stockholders
of Syra Health Corp.

Opinion
on the Financial Statements

We
have audited the accompanying balance sheets of Syra Health Corp. (the Company) as of December 31, 2024 and 2023, and the related statements
of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2024 and the
related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to
above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results
of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting
principles generally accepted in the United States of America.

Going
Concern

The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company had a cash